Study summary

A cathepsin C blocker showed a dose-dependent reduction in flare-ups

AIRLEAF trial (BI 1291583) · 322 people, phase 2 · Published January 2025, European Respiratory Journal

0.66hazard ratio for first flare-up at 2.5 mg

What was tested

BI 1291583, a once-daily pill that blocks cathepsin C (the same target as DPP-1), at three doses against placebo for 24 to 48 weeks.

What they found

What it means

Led to the phase 3 AIRTIVITY trial.

Eur Respir J, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.